import type { CompetitorRecord } from './competitor-database';

export const ADDITIONAL_COMPETITORS: CompetitorRecord[] = [
  // ── Waldenstrom's Macroglobulinemia ────────────────────────────────────────
  {
    asset_name: 'Brukinsa',
    generic_name: 'zanubrutinib',
    company: 'BeiGene',
    indication: "Waldenstrom's Macroglobulinemia",
    indication_specifics: 'Treatment of adult patients with WM, including first-line and relapsed/refractory settings',
    mechanism: 'Selective BTK inhibitor that binds covalently to BTK active site',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'ASPEN trial: VGPR rate 28.4% vs 19.5% for ibrutinib; improved cardiac safety profile',
    line_of_therapy: '1L and 2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Superior selectivity for BTK with fewer off-target kinase effects',
      'Favorable cardiac safety profile compared to ibrutinib with lower atrial fibrillation rates',
      'Head-to-head superiority in VGPR rate demonstrated in ASPEN trial',
    ],
    weaknesses: [
      'Requires twice-daily dosing which may reduce patient compliance',
      'Limited long-term follow-up data compared to ibrutinib',
      'Competitive market with established ibrutinib and emerging next-generation BTK inhibitors',
    ],
    source: 'BeiGene 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imbruvica',
    generic_name: 'ibrutinib',
    company: 'AbbVie/J&J',
    indication: "Waldenstrom's Macroglobulinemia",
    indication_specifics: 'Treatment of adult patients with WM, both treatment-naive and relapsed/refractory',
    mechanism: 'First-generation covalent BTK inhibitor that irreversibly binds to Cys481 of BTK',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'iNNOVATE trial: ORR 90% with ibrutinib + rituximab vs 47% placebo + rituximab; 30-month PFS 82% vs 28%',
    line_of_therapy: '1L and 2L+',
    partner: 'Pharmacyclics (AbbVie)/Janssen (J&J)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class BTK inhibitor with extensive long-term safety and efficacy data',
      'Broad clinical experience across multiple B-cell malignancies',
      'Strong combination data with rituximab in iNNOVATE trial',
    ],
    weaknesses: [
      'Higher rates of atrial fibrillation and cardiovascular events compared to next-gen BTK inhibitors',
      'Off-target kinase inhibition (EGFR, ITK, TEC) contributing to adverse events',
      'Losing market share to zanubrutinib due to tolerability differences',
    ],
    source: 'AbbVie/J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ixazomib',
    generic_name: 'ixazomib',
    company: 'Takeda',
    indication: "Waldenstrom's Macroglobulinemia",
    indication_specifics: 'Investigational use in relapsed/refractory WM as an oral proteasome inhibitor alternative',
    mechanism: 'Reversible proteasome inhibitor targeting the 20S proteasome beta-5 subunit',
    mechanism_category: 'proteasome_inhibitor',
    molecular_target: '20S proteasome',
    phase: 'Phase 2',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'Phase 2 study: ORR ~50% with ixazomib-dexamethasone-rituximab in R/R WM patients',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02400437'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First oral proteasome inhibitor offering convenience over IV bortezomib',
      'Non-overlapping mechanism with BTK inhibitors enables potential sequencing or combination strategies',
      'Manageable toxicity profile with lower peripheral neuropathy rates than bortezomib',
    ],
    weaknesses: [
      'Limited efficacy data specifically in WM compared to approved BTK inhibitors',
      'BTK inhibitor dominance in WM treatment landscape reduces clinical uptake potential',
      'Not yet approved for WM indication despite existing myeloma approval',
    ],
    source: 'Takeda 2024',
    last_updated: '2025-01-15',
  },

  // ── Alzheimer's Disease ────────────────────────────────────────────────────
  {
    asset_name: 'Leqembi',
    generic_name: 'lecanemab',
    company: 'Eisai/Biogen',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Treatment of early Alzheimer\'s disease with confirmed amyloid-beta pathology',
    mechanism: 'Humanized IgG1 monoclonal antibody selectively targeting amyloid-beta protofibrils',
    mechanism_category: 'anti_amyloid_antibody',
    molecular_target: 'Amyloid-beta',
    phase: 'Approved',
    primary_endpoint: 'CDR-SB',
    key_data: 'CLARITY AD trial: 27% slowing of clinical decline on CDR-SB at 18 months (p<0.001); amyloid plaque reduction of 59%',
    line_of_therapy: '1L',
    partner: 'Eisai/Biogen',
    nct_ids: ['NCT03887455'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Statistically significant slowing of cognitive decline in large Phase 3 trial',
      'Full traditional FDA approval with confirmatory CLARITY AD data',
      'Strong amyloid plaque clearance supporting amyloid hypothesis validation',
    ],
    weaknesses: [
      'ARIA (amyloid-related imaging abnormalities) occurring in ~13% of patients requiring MRI monitoring',
      'Biweekly IV infusion schedule creates logistical burden for patients and caregivers',
      'Modest absolute clinical benefit raises questions about clinical meaningfulness',
    ],
    source: 'Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kisunla',
    generic_name: 'donanemab',
    company: 'Eli Lilly',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Treatment of early symptomatic Alzheimer\'s disease with amyloid and tau pathology',
    mechanism: 'Humanized IgG1 monoclonal antibody targeting N-terminal pyroglutamate amyloid-beta (N3pG-Abeta)',
    mechanism_category: 'anti_amyloid_antibody',
    molecular_target: 'Amyloid-beta',
    phase: 'Approved',
    primary_endpoint: 'CDR-SB',
    key_data: 'TRAILBLAZER-ALZ 2: 35% slowing of decline on iADRS in low/medium tau population; 40% of patients achieved amyloid clearance and stopped dosing by 12 months',
    line_of_therapy: '1L',
    nct_ids: ['NCT04437511'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Potential for treatment discontinuation upon amyloid clearance, reducing long-term treatment burden',
      'Robust efficacy in low/medium tau subgroup with 35% slowing on iADRS',
      'Rapid amyloid clearance with majority of patients clearing plaques within 12 months',
    ],
    weaknesses: [
      'ARIA-E incidence of ~24% is higher than lecanemab, increasing safety monitoring requirements',
      'Tau-based patient stratification adds complexity to patient selection and biomarker testing',
      'Three deaths in TRAILBLAZER-ALZ 2 linked to ARIA created safety concerns',
    ],
    source: 'Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Aduhelm',
    generic_name: 'aducanumab',
    company: 'Biogen',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Treatment of Alzheimer\'s disease with confirmed amyloid-beta pathology (limited use)',
    mechanism: 'Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-beta including plaques',
    mechanism_category: 'anti_amyloid_antibody',
    molecular_target: 'Amyloid-beta',
    phase: 'Approved',
    primary_endpoint: 'CDR-SB',
    key_data: 'EMERGE trial: 22% reduction in CDR-SB decline at high dose (p=0.01); ENGAGE trial did not meet primary endpoint; accelerated approval granted 2021',
    line_of_therapy: '1L',
    nct_ids: ['NCT02477800', 'NCT02484547'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First anti-amyloid antibody to receive FDA approval, paving regulatory path for the class',
      'EMERGE trial showed significant amyloid plaque reduction and clinical benefit at high dose',
      'Established proof of concept for amyloid-targeting immunotherapy approach',
    ],
    weaknesses: [
      'Conflicting Phase 3 results between EMERGE and ENGAGE trials undermined confidence',
      'Biogen discontinued commercial efforts in 2024 due to poor market uptake',
      'Controversial accelerated approval generated significant pushback from medical community and payers',
    ],
    source: 'Biogen 2024',
    last_updated: '2025-01-15',
  },

  // ── Parkinson's Disease ────────────────────────────────────────────────────
  {
    asset_name: 'Nuplazid',
    generic_name: 'pimavanserin',
    company: 'Acadia Pharmaceuticals',
    indication: "Parkinson's Disease",
    indication_specifics: 'Treatment of hallucinations and delusions associated with Parkinson\'s disease psychosis',
    mechanism: 'Selective serotonin 5-HT2A receptor inverse agonist and antagonist without dopaminergic activity',
    mechanism_category: '5ht2a_inverse_agonist',
    molecular_target: '5-HT2A',
    phase: 'Approved',
    primary_endpoint: 'SAPS-PD (Scale for Assessment of Positive Symptoms - Parkinson\'s Disease)',
    key_data: 'ACP-103-020 trial: -5.79 point improvement on SAPS-PD vs -2.73 for placebo (p=0.001); no worsening of motor function',
    line_of_therapy: '1L for PD psychosis',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First and only FDA-approved treatment specifically for Parkinson\'s disease psychosis',
      'No dopaminergic antagonism, avoiding motor symptom worsening unlike typical antipsychotics',
      'Once-daily oral dosing with no titration requirement improves convenience',
    ],
    weaknesses: [
      'Black box warning for increased mortality in elderly dementia patients limits prescriber confidence',
      'Post-marketing safety signals and FDA advisory committee scrutiny created headwinds',
      'Modest effect size raises debate about clinical meaningfulness in real-world settings',
    ],
    source: 'Acadia Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ongentys',
    generic_name: 'opicapone',
    company: 'Bial/Neurocrine Biosciences',
    indication: "Parkinson's Disease",
    indication_specifics: 'Adjunctive treatment to levodopa/carbidopa in PD patients experiencing OFF episodes',
    mechanism: 'Third-generation COMT inhibitor with long-acting, once-daily peripheral catechol-O-methyltransferase inhibition',
    mechanism_category: 'comt_inhibitor',
    molecular_target: 'COMT',
    phase: 'Approved',
    primary_endpoint: 'OFF time',
    key_data: 'BIPARK-1 trial: -116.8 min reduction in absolute OFF time vs -56.0 min for placebo (p<0.001); no hepatotoxicity signal',
    line_of_therapy: 'Adjunctive to levodopa',
    partner: 'Neurocrine Biosciences',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Once-daily dosing and no hepatotoxicity monitoring required, unlike entacapone and tolcapone',
      'Significant reduction in OFF time as levodopa adjunct in BIPARK-1 and BIPARK-2 trials',
      'Third-generation COMT inhibitor with improved safety profile over predecessors',
    ],
    weaknesses: [
      'Crowded adjunctive PD therapy market with established entacapone and MAO-B inhibitors',
      'Dyskinesia as a common side effect due to increased levodopa exposure',
      'Limited differentiation from entacapone in clinical practice beyond convenience of dosing',
    ],
    source: 'Bial/Neurocrine 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Buntanetap',
    company: 'Annovis Bio',
    indication: "Parkinson's Disease",
    indication_specifics: 'Disease-modifying treatment targeting neurodegeneration in early Parkinson\'s disease',
    mechanism: 'Oral small molecule that inhibits translation of multiple neurotoxic proteins including alpha-synuclein, tau, and APP',
    mechanism_category: 'anti_neurodegenerative',
    molecular_target: 'Alpha-synuclein/APP/Tau mRNA translation',
    phase: 'Phase 3',
    primary_endpoint: 'UPDRS',
    key_data: 'Phase 2/3: Dose-dependent improvement in UPDRS Parts I-IV; 28% improvement in Part III motor scores at highest dose over 6 months',
    line_of_therapy: '1L disease-modifying',
    nct_ids: ['NCT05357989'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Novel multi-target mechanism addressing multiple neurotoxic proteins simultaneously',
      'Oral administration offers significant advantage over antibody-based approaches',
      'Disease-modifying potential rather than purely symptomatic relief',
    ],
    weaknesses: [
      'Small company with limited commercial infrastructure for potential launch',
      'Phase 2/3 data from relatively small patient populations requires large Phase 3 confirmation',
      'Multi-target mechanism raises selectivity and safety concerns with long-term use',
    ],
    source: 'Annovis Bio 2024',
    last_updated: '2025-01-15',
  },

  // ── Huntington's Disease ───────────────────────────────────────────────────
  {
    asset_name: 'Austedo',
    generic_name: 'deutetrabenazine',
    company: 'Teva Pharmaceutical',
    indication: "Huntington's Disease",
    indication_specifics: 'Treatment of chorea associated with Huntington\'s disease',
    mechanism: 'Deuterated VMAT2 inhibitor that reduces dopamine signaling by inhibiting vesicular monoamine transporter 2',
    mechanism_category: 'vmat2_inhibitor',
    molecular_target: 'VMAT2',
    phase: 'Approved',
    primary_endpoint: 'TMS (Total Maximal Chorea Score)',
    key_data: 'ARC-HD and FIRST-HD trials: -4.4 point improvement in TMS vs -1.9 for placebo (p<0.001); improved tolerability over tetrabenazine',
    line_of_therapy: '1L for HD chorea',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Deuterium modification provides longer half-life and more stable plasma levels than tetrabenazine',
      'Reduced dosing frequency (twice daily vs three times daily) improves compliance',
      'Lower rates of depression and somnolence compared to tetrabenazine in clinical studies',
    ],
    weaknesses: [
      'Only treats chorea symptoms without addressing underlying disease progression',
      'CYP2D6 poor metabolizer status requires dose adjustment and pharmacogenomic testing',
      'Black box warning for depression and suicidality in patients with Huntington\'s disease',
    ],
    source: 'Teva 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xenazine',
    generic_name: 'tetrabenazine',
    company: 'Lundbeck',
    indication: "Huntington's Disease",
    indication_specifics: 'Treatment of chorea associated with Huntington\'s disease',
    mechanism: 'VMAT2 inhibitor that depletes monoamines (dopamine, serotonin, norepinephrine) from nerve terminals',
    mechanism_category: 'vmat2_inhibitor',
    molecular_target: 'VMAT2',
    phase: 'Approved',
    primary_endpoint: 'TMS (Total Maximal Chorea Score)',
    key_data: 'TETRA-HD trial: -5.0 unit reduction in TMS vs -1.5 for placebo (p<0.001); first FDA-approved treatment for HD chorea (2008)',
    line_of_therapy: '1L for HD chorea',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First FDA-approved treatment for Huntington\'s disease chorea with over 15 years of clinical experience',
      'Well-characterized mechanism of action with robust efficacy on chorea reduction',
      'Established treatment standard providing a benchmark for newer VMAT2 inhibitors',
    ],
    weaknesses: [
      'Three-times-daily dosing and complex titration schedule reduce patient adherence',
      'Higher rates of depression, somnolence, and parkinsonism compared to deutetrabenazine',
      'Short half-life leads to peak-trough fluctuations in symptom control',
    ],
    source: 'Lundbeck 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'PTC518',
    company: 'PTC Therapeutics',
    indication: "Huntington's Disease",
    indication_specifics: 'Disease-modifying treatment targeting huntingtin protein reduction in Huntington\'s disease',
    mechanism: 'Oral small molecule splicing modifier that promotes inclusion of a premature stop codon in HTT mRNA',
    mechanism_category: 'splicing_modifier',
    molecular_target: 'HTT mRNA',
    phase: 'Phase 2',
    primary_endpoint: 'UHDRS-TFC',
    key_data: 'PIVOT-HD Phase 2: Dose-dependent reduction of mutant huntingtin protein of up to 30% in CSF; well-tolerated across all dose levels',
    line_of_therapy: '1L disease-modifying',
    nct_ids: ['NCT05358717'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Oral administration is a major advantage over intrathecal antisense oligonucleotide approaches',
      'Novel splicing mechanism offers differentiated approach following tominersen failure',
      'Demonstrated dose-dependent huntingtin lowering in CSF providing pharmacodynamic proof of concept',
    ],
    weaknesses: [
      'HTT-lowering approach faces skepticism after Roche tominersen Phase 3 failure',
      'Long-term safety of chronic huntingtin protein reduction remains unknown',
      'Phase 2 stage with significant clinical and regulatory risk ahead before potential approval',
    ],
    source: 'PTC Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ── Friedreich's Ataxia ────────────────────────────────────────────────────
  {
    asset_name: 'Skyclarys',
    generic_name: 'omaveloxolone',
    company: 'Reata Pharmaceuticals/Biogen',
    indication: "Friedreich's Ataxia",
    indication_specifics: 'Treatment of Friedreich\'s ataxia in adults and adolescents aged 16 years and older',
    mechanism: 'Nrf2 activator that enhances antioxidant gene expression and restores mitochondrial function',
    mechanism_category: 'nrf2_activator',
    molecular_target: 'Nrf2/KEAP1',
    phase: 'Approved',
    primary_endpoint: 'mFARS (modified Friedreich Ataxia Rating Scale)',
    key_data: 'MOXIe Part 2 trial: -1.55 point improvement in mFARS vs placebo at 48 weeks (p=0.014); first FDA-approved treatment for FA (2023)',
    line_of_therapy: '1L',
    partner: 'Biogen (acquired Reata)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First and only FDA-approved treatment for Friedreich\'s ataxia, addressing major unmet need',
      'Oral once-daily dosing is convenient for chronic administration',
      'Nrf2 pathway activation addresses core mitochondrial dysfunction underlying the disease',
    ],
    weaknesses: [
      'Modest effect size on mFARS with ongoing debate about clinical meaningfulness',
      'Hepatotoxicity risk requires baseline and periodic liver function monitoring',
      'Not approved for patients under 16 years, excluding a portion of the FA population',
    ],
    source: 'Biogen/Reata 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'RT001',
    company: 'Larimar Therapeutics',
    indication: "Friedreich's Ataxia",
    indication_specifics: 'Disease-modifying treatment aimed at restoring frataxin protein levels in Friedreich\'s ataxia',
    mechanism: 'Recombinant human frataxin (CTI-1601) protein replacement therapy delivered via subcutaneous injection',
    mechanism_category: 'frataxin_replacement',
    molecular_target: 'Frataxin',
    phase: 'Phase 2/3',
    primary_endpoint: 'mFARS (modified Friedreich Ataxia Rating Scale)',
    key_data: 'Phase 1/2: Demonstrated dose-dependent increase in frataxin levels up to 73% of normal in PBMCs; Phase 2/3 REVEAL trial ongoing',
    line_of_therapy: '1L disease-modifying',
    nct_ids: ['NCT05579327'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Directly addresses root cause of FA by replacing deficient frataxin protein',
      'Demonstrated meaningful frataxin level increases in early clinical data',
      'Disease-modifying potential beyond symptomatic treatment offered by omaveloxolone',
    ],
    weaknesses: [
      'Subcutaneous injection requirement may reduce patient acceptance compared to oral options',
      'Protein replacement approach requires chronic administration with uncertain long-term immunogenicity',
      'Small biotech with limited resources for late-stage development and potential commercialization',
    ],
    source: 'Larimar Therapeutics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vatiquinone',
    company: 'PTC Therapeutics',
    indication: "Friedreich's Ataxia",
    indication_specifics: 'Treatment of Friedreich\'s ataxia targeting oxidative stress pathways',
    mechanism: 'Oral 15-lipoxygenase inhibitor that reduces oxidative stress and ferroptosis in mitochondria',
    mechanism_category: 'oxidative_stress_modulator',
    molecular_target: '15-Lipoxygenase',
    phase: 'Phase 3',
    primary_endpoint: 'mFARS (modified Friedreich Ataxia Rating Scale)',
    key_data: 'MOVE-FA Phase 3: Trend toward improvement in mFARS but primary endpoint not met (p=0.066); post-hoc analysis showed benefit in ambulatory subgroup',
    line_of_therapy: '1L',
    nct_ids: ['NCT04577352'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Oral once-daily dosing provides convenience advantage over injectable approaches',
      'Novel ferroptosis-targeting mechanism addresses key pathological pathway in FA',
      'Signal of efficacy in ambulatory patients suggests potential for enriched population study',
    ],
    weaknesses: [
      'MOVE-FA Phase 3 trial missed primary endpoint, creating significant regulatory uncertainty',
      'Reliance on post-hoc subgroup analysis weakens the evidence base for efficacy',
      'Competitive landscape now includes approved Skyclarys, raising bar for differentiation',
    ],
    source: 'PTC Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ── Sjogren's Syndrome ────────────────────────────────────────────────────
  {
    asset_name: 'Ianalumab',
    company: 'Novartis',
    indication: "Sjogren's Syndrome",
    indication_specifics: 'Treatment of moderate-to-severe primary Sjogren\'s syndrome with systemic involvement',
    mechanism: 'Fully human anti-BAFF receptor monoclonal antibody that depletes B cells via ADCC and blocks BAFF signaling',
    mechanism_category: 'anti_baff_receptor',
    molecular_target: 'BAFF-R',
    phase: 'Phase 3',
    primary_endpoint: 'ESSDAI',
    key_data: 'Phase 2b (NCT02962895): Significant improvement in ESSDAI at week 24 vs placebo; dose-dependent B cell depletion and reduction in disease biomarkers',
    line_of_therapy: '1L systemic',
    nct_ids: ['NCT02962895', 'NCT05349890'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Dual mechanism of BAFF-R blockade plus B cell depletion provides deep B cell targeting',
      'Subcutaneous self-administration enables convenient dosing outside clinical settings',
      'Novartis large-scale development capability and commercial infrastructure for rare autoimmune indications',
    ],
    weaknesses: [
      'No approved therapies for systemic Sjogren\'s creates regulatory uncertainty around endpoints and trial design',
      'Risk of infection from profound B cell depletion requires careful monitoring',
      'Phase 3 results not yet available, and prior B cell-targeting approaches in Sjogren\'s have had mixed outcomes',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nipocalimab',
    company: 'Janssen (J&J)',
    indication: "Sjogren's Syndrome",
    indication_specifics: 'Treatment of primary Sjogren\'s syndrome targeting pathogenic autoantibody reduction',
    mechanism: 'Anti-FcRn monoclonal antibody that accelerates IgG catabolism, reducing circulating pathogenic autoantibodies',
    mechanism_category: 'fcrn_inhibitor',
    molecular_target: 'FcRn',
    phase: 'Phase 2',
    primary_endpoint: 'ESSDAI',
    key_data: 'Phase 2 in Sjogren\'s ongoing; mechanism validated in other autoimmune conditions with ~70% reduction in total IgG levels',
    line_of_therapy: '1L systemic',
    nct_ids: ['NCT05405907'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'FcRn inhibition provides rapid and significant reduction of pathogenic autoantibodies',
      'Mechanism agnostic to antibody specificity, addressing multiple autoantibody-driven pathways simultaneously',
      'J&J/Janssen commercial and development resources support broad clinical program across autoimmune diseases',
    ],
    weaknesses: [
      'Broad IgG reduction may impair humoral immunity and increase infection susceptibility',
      'Early-stage in Sjogren\'s specifically, with limited disease-specific efficacy data',
      'IV infusion requirement reduces convenience compared to subcutaneous alternatives',
    ],
    source: 'Janssen/J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Deucravacitinib',
    generic_name: 'deucravacitinib',
    company: 'Bristol-Myers Squibb',
    indication: "Sjogren's Syndrome",
    indication_specifics: 'Treatment of moderate-to-severe primary Sjogren\'s syndrome targeting JAK/TYK2-mediated inflammation',
    mechanism: 'Allosteric TYK2 inhibitor that selectively binds the TYK2 regulatory domain, blocking IL-12, IL-23, and type I IFN signaling',
    mechanism_category: 'tyk2_inhibitor',
    molecular_target: 'TYK2',
    phase: 'Phase 2',
    primary_endpoint: 'ESSDAI',
    key_data: 'Phase 2 POETYK-SjS trial ongoing; deucravacitinib approved for psoriasis (SOTYKTU) with validated TYK2 selectivity and safety profile',
    line_of_therapy: '1L systemic',
    nct_ids: ['NCT05668065'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Selective TYK2 inhibition avoids JAK1/2/3-related safety concerns including thrombosis and cytopenias',
      'Oral once-daily dosing is highly convenient for chronic autoimmune disease management',
      'Type I interferon pathway blockade is mechanistically relevant given interferon signature in Sjogren\'s',
    ],
    weaknesses: [
      'No Sjogren\'s-specific efficacy data yet available from ongoing Phase 2 trial',
      'Regulatory scrutiny of JAK-class inhibitors may create hurdles despite TYK2 selectivity differentiation',
      'Competitive landscape with multiple mechanism classes advancing in Sjogren\'s simultaneously',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },
];
